|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Gilbert MR and
Chakravarti A: Chemoradiotherapy in malignant glioma: Standard of
care and future directions. J Clin Oncol. 25:4127–4136. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lima FRS, Kahn SA, Soletti RC, Biasoli D,
Alves T, da Fonseca AC, Garcia C, Romão L, Brito J, Holanda-Afonso
R, et al: Glioblastoma: Therapeutic challenges, what lies ahead.
Biochim Biophys Acta. 1826:338–349. 2012.PubMed/NCBI
|
|
5
|
Huse JT, Holland E and DeAngelis LM:
Glioblastoma: Molecular analysis and clinical implications. Annu
Rev Med. 64:59–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balça-Silva J, Matias D, do Carmo A, Girão
H, Moura-Neto V, Sarmento-Ribeiro AB and Lopes MC: Tamoxifen in
combination with temozolomide induce a synergistic inhibition of
PKC-pan in GBM cell lines. Biochim Biophys Acta. 1850:722–732.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carmo A, Carvalheiro H, Crespo I, Nunes I
and Lopes MC: Effect of temozolomide on the U-118 glioma cell line.
Oncol Lett. 2:1165–1170. 2011.PubMed/NCBI
|
|
8
|
do Carmo A, Patricio I, Cruz MT,
Carvalheiro H, Oliveira CR and Lopes MC: CXCL12/CXCR4 promotes
motility and proliferation of glioma cells. Cancer Biol Ther.
9:56–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hattermann K and Mentlein R: An infernal
trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in
tumor biology. Ann Anat. 195:103–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Atsina KB, Himes BT, Strohbehn GW
and Saltzman WM: Novel delivery strategies for glioblastoma. Cancer
J. 18:89–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Safa AR, Saadatzadeh MR, Cohen-Gadol AA,
Pollok KE and Bijangi-Vishehsaraei K: Glioblastoma stem cells
(GSCs) epigenetic plasticity and interconversion between
differentiated non-GSCs and GSCs. Genes Dis. 2:152–163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thirant C, Bessette B, Varlet P, Puget S,
Cadusseau J, Tavares SR, Studler JM, Silvestre DC, Susini A, Villa
C, et al: Clinical relevance of tumor cells with stem-like
properties in pediatric brain tumors. PLoS One. 6:e163752011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bogush T, Dudko E, Bogush E, Polotsky B,
Tjulandin S and Davydov M: Tamoxifen non-estrogen receptor mediated
molecular targets. Oncol Rev. 6:e152012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kahn SA, Biasoli D, Garcia C, Geraldo LH,
Pontes B, Sobrinho M, Frauches AC, Romão L, Soletti RC, Assunção
FS, et al: Equinatoxin II potentiates temozolomide- and
etoposide-induced glioblastoma cell death. Curr Top Med Chem.
12:2082–2093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faria J, Romão L, Martins S, Alves T,
Mendes FA, de Faria GP, Hollanda R, Takiya C, Chimelli L, Morandi
V, et al: Interactive properties of human glioblastoma cells with
brain neurons in culture and neuronal modulation of glial laminin
organization. Differentiation. 74:562–572. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Linn SC, Giaccone G, van Diest PJ,
Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM
and Baak JP: Prognostic relevance of P-glycoprotein expression in
breast cancer. Ann Oncol. 6:679–685. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calatozzolo C, Gelati M, Ciusani E,
Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A,
Vitellaro-Zuccarello L, Croci D, et al: Expression of drug
resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-π in human
glioma. J Neurooncol. 74:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonçalves AC, Cortesão E, Oliveiros B,
Alves V, Espadana AI, Rito L, Magalhães E, Lobão MJ, Pereira A,
Costa JM Nascimento, et al: Oxidative stress and mitochondrial
dysfunction play a role in myelodysplastic syndrome development,
diagnosis, and prognosis: A pilot study. Free Radic Res.
49:1081–1094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Towbin H, Staehelin T and Gordon J:
Immunoblotting in the clinical laboratory. J Clin Chem Clin
Biochem. 27:495–501. 1989.PubMed/NCBI
|
|
21
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rittierodt M and Harada K: Repetitive
doxorubicin treatment of glioblastoma enhances the PGP expression -
a special role for endothelial cells. Exp Toxicol Pathol. 55:39–44.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Borowski E, Bontemps-Gracz MM and
Piwkowska A: Strategies for overcoming ABC-transporters-mediated
multidrug resistance (MDR) of tumor cells. Acta Biochim Pol.
52:609–627. 2005.PubMed/NCBI
|
|
24
|
Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC,
Feng BH and Chen ZP: Enhanced MGMT expression contributes to
temozolomide resistance in glioma stem-like cells. Chin J Cancer.
33:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hegi ME, Diserens A-C, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He W, Liu R, Yang SH and Yuan F:
Chemotherapeutic effect of tamoxifen on temozolomide-resistant
gliomas. Anticancer Drugs. 26:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Couldwell WT, Hinton DR, He S, Chen TC,
Sebat I, Weiss MH and Law RE: Protein kinase C inhibitors induce
apoptosis in human malignant glioma cell lines. FEBS Lett.
345:43–46. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang W, Couldwell WT, Song H, Takano T,
Lin JH and Nedergaard M: Tamoxifen-induced enhancement of calcium
signaling in glioma and MCF-7 breast cancer cells. Cancer Res.
60:5395–5400. 2000.PubMed/NCBI
|
|
29
|
OBrian CA, Liskamp RM, Solomon DH and
Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer
Res. 45:2462–2465. 1985.PubMed/NCBI
|
|
30
|
Kamburoğlu G, Kiratli H, Söylemezoğlu F
and Bilgiç S: Clinicopathological parameters and expression of
P-glycoprotein and MRP-1 in retinoblastoma. Ophthalmic Res.
39:191–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hui AM, Zhang W, Chen W, Xi D, Purow B,
Friedman GC and Fine HA: Agents with selective estrogen receptor
(ER) modulator activity induce apoptosis in vitro and in vivo in
ER-negative glioma cells. Cancer Res. 64:9115–9123. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deck JH, Eng LF, Bigbee J and Woodcock SM:
The role of glial fibrillary acidic protein in the diagnosis of
central nervous system tumors. Acta Neuropathol. 42:183–190. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Altaner C and Altanerova V: Stem cell
based glioblastoma gene therapy. Neoplasma. 59:756–760. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jackson M, Hassiotou F and Nowak A:
Glioblastoma stem-like cells: At the root of tumor recurrence and a
therapeutic target. Carcinogenesis. 36:177–185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garcia C, Dubois LG, Xavier AL, Geraldo
LH, da Fonseca AC, Correia AH, Meirelles F, Ventura G, Romão L,
Canedo NH, et al: The orthotopic xenotransplant of human
glioblastoma successfully recapitulates
glioblastoma-microenvironment interactions in a
non-immunosuppressed mouse model. BMC Cancer. 14:9232014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tóth K, Vaughan MM, Peress NS, Slocum HK
and Rustum YM: MDR1 P-glycoprotein is expressed by endothelial
cells of newly formed capillaries in human gliomas but is not
expressed in the neovasculature of other primary tumors. Am J
Pathol. 149:853–858. 1996.PubMed/NCBI
|
|
38
|
Sun H, Dai H, Shaik N and Elmquist WF:
Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 55:83–105.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cordon-Cardo C, OBrien JP, Casals D,
Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR:
Multidrug-resistance gene (P-glycoprotein) is expressed by
endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci
USA. 86:695–698. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schaich M, Kestel L, Pfirrmann M, Robel K,
Illmer T, Kramer M, Dill C, Ehninger G, Schackert G and Krex D: A
MDR1 (ABCB1) gene single nucleotide polymorphism predicts
outcome of temozolomide treatment in glioblastoma patients. Ann
Oncol. 20:175–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tomaszowski KH, Schirrmacher R and Kaina
B: Multidrug efflux pumps attenuate the effect of MGMT inhibitors.
Mol Pharm. 12:3924–3934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Diaz A and Leon K: Therapeutic approaches
to target cancer stem cells. Cancers (Basel). 3:3331–3352. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ortensi B, Setti M, Osti D and Pelicci G:
Cancer stem cell contribution to glioblastoma invasiveness. Stem
Cell Res Ther. 4:182013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Seymour T, Nowak A and Kakulas F:
Targeting aggressive cancer stem cells in glioblastoma. Front
Oncol. 5:1592015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cox JL, Wilder PJ, Desler M and Rizzino A:
Elevating SOX2 levels deleteriously affects the growth of
medulloblastoma and glioblastoma cells. PLoS One. 7:e440872012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Callaghan R and Higgins C: Interaction of
tamoxifen with the multidrug resistance P-glycoprotein. Br J
Cancer. 71:294–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Di Cristofori A, Carrabba G, Lanfranchi G,
Menghetti C, Rampini P and Caroli M: Continuous tamoxifen and
dose-dense temozolomide in recurrent glioblastoma. Anticancer Res.
33:3383–3389. 2013.PubMed/NCBI
|
